EMPACT-MI trial; empagliflozin; SGTL2i; MI; heart failure

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Targeting cardiac energetics with cardiac mitotrope in nonobstructive HCM
Targeting cardiac energetics with cardiac mitotrope in nonobstructive HCM
ACC.24
Targeting cardiac energetics with cardiac mitotrope in nonobstructive HCM
- Martin Maron, MD
Long-term improvements in daily steps with gamification and financial incentives in patients at risk for CV events
Long-term improvements in daily steps with gamification and financial incentives in patients at risk for CV events
ACC.24
Long-term improvements in daily steps with gamification and financial incentives in patients at risk for CV events
- Alexander Fanaroff, MD
Angiotensinogen RNAi therapeutic lowers blood pressure in combination with standard antihypertensive
Angiotensinogen RNAi therapeutic lowers blood pressure in combination with standard antihypertensive
ACC.24
Angiotensinogen RNAi therapeutic lowers blood pressure in combination with standard antihypertensive
- Akshay S. Desai, MD
Preventive PCI versus optimal medical therapy only for vulnerable plaques
Preventive PCI versus optimal medical therapy only for vulnerable plaques
ACC.24
Preventive PCI versus optimal medical therapy only for vulnerable plaques
- Marc Bonaca, MD

No effect on the primary endpoint with SGLT2i post-MI, but significant effect on HF hospitalizations